LivaNova PLC $LIVN is Dark Forest Capital Management LP's 7th Largest Position

Key Points

• Dark Forest Capital Management LP significantly increased its holdings in LivaNova PLC by 960.1%, owning 275,054 shares worth approximately $10.8 million.
• Several other hedge funds also boosted their stakes in LivaNova, with UMB Bank n.a. raising its holdings by 340.5% during the first quarter.
• Analysts have shown positive sentiment towards LivaNova, with a consensus rating of "Buy" and a consensus price target of $59.71.

Dark Forest Capital Management LP grew its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 960.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 275,054 shares of the company's stock after purchasing an additional 249,107 shares during the quarter. LivaNova makes up approximately 0.5% of Dark Forest Capital Management LP's portfolio, making the stock its 7th biggest position. Dark Forest Capital Management LP owned 0.50% of LivaNova worth $10,804,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in LIVN. UMB Bank n.a. boosted its stake in shares of LivaNova by 340.5% during the first quarter. UMB Bank n.a. now owns 837 shares of the company's stock valued at $33,000 after purchasing an additional 647 shares during the period. CWM LLC boosted its stake in shares of LivaNova by 52.3% during the first quarter. CWM LLC now owns 871 shares of the company's stock valued at $34,000 after purchasing an additional 299 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in shares of LivaNova by 415.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company's stock valued at $58,000 after purchasing an additional 1,184 shares during the period. Central Pacific Bank Trust Division boosted its stake in shares of LivaNova by 7.0% during the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock valued at $173,000 after purchasing an additional 290 shares during the period. Finally, Corton Capital Inc. purchased a new stake in shares of LivaNova during the fourth quarter valued at approximately $214,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Stock Down 0.3%

LivaNova stock traded down $0.18 on Friday, hitting $57.97. 958,459 shares of the stock traded hands, compared to its average volume of 633,219. The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31. The firm has a market cap of $3.17 billion, a P/E ratio of -14.90 and a beta of 0.97. The business's fifty day simple moving average is $48.67 and its 200 day simple moving average is $43.68. LivaNova PLC has a 1 year low of $32.48 and a 1 year high of $58.42.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $0.84 by $0.21. The business had revenue of $352.50 million during the quarter, compared to analyst estimates of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The company's revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.93 earnings per share. As a group, sell-side analysts forecast that LivaNova PLC will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on LIVN. Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research note on Wednesday. Barclays raised their price target on LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 21st. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target for the company in a research note on Tuesday, May 20th. Finally, Wall Street Zen raised LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, LivaNova currently has a consensus rating of "Buy" and a consensus price target of $59.71.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.